Business Context and Reporting Period
Company: Coherus BioSciences, Inc.
Filing Type: Form 8-K (Current Report)
Date: July 5, 2017
Event: Termination of development partnership for etanercept biosimilar candidate CHS-0214 in Japan.
Key Financial Metrics
This filing is a current report regarding a specific corporate event and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
- Partnership Termination: Daiichi Sankyo Company, Limited announced the decision to discontinue development of CHS-0214 in Japan and conclude the global open-label safety extension study in rheumatoid arthritis.
- Regained Rights: Coherus regained the rights to develop and commercialize CHS-0214 in Japan pursuant to the January 23, 2012 License Agreement.
- Reasoning: The decision was driven by projected biosimilar pricing constraints and the inability to establish a manufacturing process capable of supplying the product at a commercially viable cost.
Outlook, Risks, and Management Commentary
Management Commentary: The Company accepted Daiichi Sankyo's decision. Management noted that selling prices for an Enbrel biosimilar in Japan were anticipated to be significantly lower than projected at the inception of the 2012 Agreement, severely constraining potential economic profit.
Risks and Contingencies: The primary risk identified is the economic viability of commercializing CHS-0214 in Japan without the partner's support, given the pricing environment and manufacturing cost challenges.
Investor Verification Checklist
- Verify the specific terms of the January 23, 2012 License Agreement regarding the reversion of rights to Coherus.
- Assess the current cost structure and manufacturing capabilities required to commercialize CHS-0214 in Japan independently.
- Review current market pricing for etanercept biosimilars in Japan to validate the "significantly lower" price projection cited by management.
- Determine if the discontinuation of the global safety extension study impacts regulatory pathways in other regions.